Dataset Information


FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.

ABSTRACT: BACKGROUND:High-grade serous ovarian carcinoma (HGSOC) is generally associated with a very dismal prognosis. Nevertheless, patients with similar clinicopathological characteristics can have markedly different clinical outcomes. Our aim was the identification of novel molecular determinants influencing survival. METHODS:Gene expression profiles of extreme HGSOC survivors (training set) were obtained by microarray. Differentially expressed genes (DEGs) and enriched signalling pathways were determined. A prognostic signature was generated and validated on curatedOvarianData database through a meta-analysis approach. The best prognostic biomarker from the signature was confirmed by RT-qPCR and by immunohistochemistry on an independent validation set. Cox regression model was chosen for survival analysis. RESULTS:Eighty DEGs and the extracellular matrix-receptor (ECM-receptor) interaction pathway were associated to extreme survival. A 10-gene prognostic signature able to correctly classify patients with 98% of accuracy was identified. By an 'in-silico' meta-analysis, overexpression of FXYD domain-containing ion transport regulator 5 (FXYD5), also known as dysadherin, was confirmed in HGSOC short-term survivors compared to long-term ones. Its prognostic and predictive power was then successfully validated, both at mRNA and protein level, first on training than on validation sample set. CONCLUSION:We demonstrated the possible involvement of FXYD5 and ECM-receptor interaction signal pathway in HCSOC survival and prognosis.


PROVIDER: S-EPMC6889357 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-11-14 | GSE131978 | GEO
2019-01-01 | S-EPMC6908519 | BioStudies
2020-01-01 | S-EPMC6997076 | BioStudies
2017-01-01 | S-EPMC5451504 | BioStudies
2008-01-01 | S-EPMC3042856 | BioStudies
2020-01-01 | S-EPMC7101203 | BioStudies
2021-01-01 | S-EPMC7917425 | BioStudies
2019-01-01 | S-EPMC6925684 | BioStudies
2016-01-01 | S-EPMC4920254 | BioStudies
2020-01-01 | S-EPMC7557892 | BioStudies